With an improved median survival of 6.2 years, lung transplantation has become an
increasingly acceptable treatment option for end-stage lung disease. Besides survival …

Lung transplantation can be a life-saving procedure for those with end-stage lung diseases.
Unfortunately, long term graft and patient survival are limited by both acute and chronic …

Cochrane, Maria Crespo Leiro, Anne Dipchand, Brian Feingold, Kathleen Grady, Edward
Horn, Maryl Johnson, Donna Mancini, Sean Pinney, Heather Ross, Kari Wujcik, Andreas …

In 2014, the Immunosuppressive Drugs Scientific Committee of the International Association
of Therapeutic Drug Monitoring and Clinical Toxicology called a meeting of international …

In a randomized, open-label trial, everolimus was compared to cyclosporine in 115 de novo
heart transplant recipients. Patients were assigned within 5 days posttransplant to low …

Background. Benefits of conversion from calcineurin inhibitor (CNI) to mammalian target of
rapamycin inhibitor-based immunosuppression in long-term kidney transplant patients …

Since the first heart transplantation (HT) in 1967, survival has steadily improved. Issues
related to over-and under-immunosuppression are, however, still common following HT …

In a randomized, open-label trial, de novo heart transplant recipients were randomized to
everolimus (3–6 ng/mL) with reduced-exposure calcineurin inhibitor (CNI; cyclosporine) to …

As the risk of graft loss due to acute rejection has declined, the goal of post-transplant
management has switched to long-term preservation of organ function. Minimizing …

Cardiac allograft vasculopathy remains a major limiting factor in the long-term survival of the
heart transplant recipient. Our understanding of its pathogenesis is continuously evolving as …